Trial result ·
Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at adults with immune thrombocytopenia, or ITP. All 28 people had ITP that steroid drugs did not keep in check. All had taken eltrombopag before without a good or lasting result. They took eltrombopag plus cyclosporine A for 8 weeks. Those who did well kept taking the drugs. There was only one group in this study. The team tracked people for a median of 32.46 months.
What they found
Of the 25 people who took the drugs for 8 weeks, 23 responded. Of these 25, 18 had a full response. In the long run, the drugs failed in 15 of the 28 people. Side effects that made people stop for good led to 8 of these failures. Side effects showed up in 24 people, and 4 people had severe ones. 2 people died from infections. No blood clots were seen. After stopping, 2 people took the same drugs again and got a full response. A higher bleeding score at the start was linked to failure.
What it means for patients
The authors say this drug pair gave a high early response. For some people, ITP stayed under control for a long time. Side effects that made people stop were a key cause of failure. The 2 deaths from infection show the need to pick people with care. They also show the need to watch closely for infection.
Why it is not certain yet
Only 28 people took part. There was no group on other drugs to compare with. The findings on bleeding scores and taking the drugs again were only early checks. There were too few failures to rule out other factors. The authors say larger, controlled studies must check these 2 early findings.
Source
Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up.
PubMed · PMID 42780154We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Immune thrombocytopenia (ITP) publications